Trial Profile

A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plamotamab (Primary) ; Plamotamab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Xencor

06 Nov 2024 According to a Xencor media release, data from subcutaneous dosing cohorts in patients with relapsed or refractory non-Hodgkin's lymphoma will be presented at the 66th American Society of Hematology Annual Meeting.
09 Sep 2024 According to a Xencor media release, company has completed a Phase 1 clinical study of plamotamab in hematologic cancers, completing enrollment in late 2023.
09 Sep 2024 Status changed from active, no longer recruiting to completed, according to a Xencor media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com